Explore

Dallas Clinical Trial Explores New ALS Treatment Targeting Immune System

Dallas Clinical Trial Explores New ALS Treatment Targeting Immune System

A clinical trial in Dallas is testing a new treatment for amyotrophic lateral sclerosis (ALS) that targets the immune system, offering hope to patients and doctors. The trial, known as ALSTARS, is evaluating an investigational therapy called COYA 302, which aims to improve the function of regulatory T cells. These immune cells help control inflammation, which is believed to contribute to the progression of ALS. The trial is being conducted at Texas Neurology in Dallas and other sites across the U.S. and Canada. Participants are randomly assigned to receive COYA 302 or a placebo for 24 weeks, with an extension phase for those who complete the initial study. The study's goal is to assess the safety and effectiveness of the treatment, which represents a novel approach by focusing on the immune system rather than directly on nerve cells.

Columbia's Alzheimer's Research Center Advances Understanding of Disease Origins

Columbia's Alzheimer's Research Center Advances Understanding of Disease Origins

At Columbia University's Alzheimer's Research Center, scientists are making strides in understanding the origins of Alzheimer's disease. Led by Dr. Scott Small, the team is focusing on the role of endosomes, organelles within cells that are likened to a train system's Grand Central Station. These endosomes are believed to be the first organelles to malfunction in Alzheimer's, leading to a cascade of cellular dysfunction. Dr. Yasir Qureshi, a colleague of Dr. Small, is working on translating findings from mouse models to human brains, aiming to develop drugs that can address these cellular issues. The research is still in the preclinical stage, but the team is optimistic about the potential for breakthroughs in treatment.

Experimental Alzheimer's Surgery Banned in China After Thousands Undergo Procedure

Experimental Alzheimer's Surgery Banned in China After Thousands Undergo Procedure

An experimental surgery aimed at treating Alzheimer's disease by enhancing the clearance of Alzheimer's-associated proteins from the brain has been banned in China. The procedure, known as deep cervical lymphovenous anastomosis (DCLVA), involves connecting the lymphatic system to nearby veins to remove proteins like beta-amyloid and tau, which are associated with Alzheimer's. Despite the ban, more than 2,000 people in China are believed to have undergone the surgery, which was initially developed by Xie Qingping at Hangzhou Qiushi Hospital. The procedure gained attention after a video showed a man with Alzheimer's walking again post-surgery. However, the Chinese National Health Commission banned the procedure outside of research settings due to a lack of evidence on its safety and effectiveness. Initial trials in the US and Singapore suggest the surgery is safe for up to six months, with some cognitive improvements noted, but these trials were not randomized or blinded.

Study Links Early-Life Sugar Restriction to Lower Alzheimer's Risk

Study Links Early-Life Sugar Restriction to Lower Alzheimer's Risk

A recent study published in the journal npj Aging suggests that individuals who experienced sugar restriction during the first 1,000 days after conception have a significantly lower risk of developing Alzheimer's disease later in life. The research, which analyzed data from over 60,000 participants in the UK Biobank, found that those exposed to sugar rationing during early childhood had a 46% lower risk of Alzheimer's compared to those who were not. The study also noted reduced risks of dementia, anxiety, and depression among this group. The findings were derived from a natural experiment during World War II when sugar was heavily rationed in the UK, providing a unique opportunity to study the long-term effects of early-life nutrition on brain health.

Traditional Chinese Medicine Shows Promise in Treating Neurodegenerative Disorders

Traditional Chinese Medicine Shows Promise in Treating Neurodegenerative Disorders

A recent review has explored the potential of Traditional Chinese Medicine (TCM) in treating neurodegenerative diseases (NDDs) such as Alzheimer's, Parkinson's, and Huntington's diseases. The study highlights cellular senescence as a key factor in the pathogenesis of these disorders, characterized by irreversible cell cycle arrest and the secretion of pro-inflammatory cytokines. TCM-derived compounds, including ginsenosides, ginkgo biloba extract, and curcumin, have shown promise in modulating cellular senescence and alleviating neurodegeneration. The review examines the molecular signaling pathways linking cellular senescence to NDDs and discusses the translational potential of these natural compounds for clinical application.

Intermittent Hypoxia Training Explored as Non-Pharmacological Therapy for PTSD

Intermittent Hypoxia Training Explored as Non-Pharmacological Therapy for PTSD

Recent research has delved into the effects of intermittent hypoxia training (IHT) as a non-pharmacological therapy for stress-related pathologies, particularly PTSD. The study compared the outcomes of three hypoxic regimes—intermittent normobaric hypoxia, hypobaric hypoxia, and chemical hypoxia—on rats with PTSD induced by single prolonged stress. The findings revealed that mild IHT was the only regimen to produce significant anxiolytic effects specific to PTSD, reducing anxiety-like behavior in the animals. The study also noted that all three hypoxic interventions significantly reduced HIF-1α mRNA and strongly reduced PAI-1, irrespective of trauma status. The research suggests that the modality of hypoxia, rather than hypoxia itself, determines the behavioral and molecular responses in PTSD, with mild IHT uniquely normalizing both in traumatized animals.

Framework for Designing Disordered Proteins Developed by Researchers

Framework for Designing Disordered Proteins Developed by Researchers

Researchers at Washington University School of Medicine and Syracuse University have developed a computational framework for designing intrinsically disordered proteins (IDRs). These proteins, which lack a stable 3D structure, play crucial roles in various cellular processes and diseases. The new tool, named GOOSE, allows scientists to design synthetic IDRs, facilitating the exploration of their functions. This advancement could accelerate research in understanding protein behavior and developing treatments for diseases like cancer and neurodegeneration. The framework enables the creation of custom-built disordered proteins, potentially leading to breakthroughs in medical and biological research.

Research Suggests Inflammation May Trigger 'Out-of-Body' Experiences

Research Suggests Inflammation May Trigger 'Out-of-Body' Experiences

Emerging research suggests that inflammation may be linked to dissociation, a mental state characterized by 'out-of-body' experiences and feelings of unreality. The study indicates that trauma-induced stress responses can lead to chronic inflammation, potentially contributing to dissociative symptoms. This research is part of a broader exploration of the role of the immune system in mental health conditions. While the findings are preliminary, they suggest that anti-inflammatory treatments could be explored as potential therapies for dissociative disorders.

Gene Therapy Enables Teen to Walk Independently, Targeting Epilepsy's Genetic Root

Gene Therapy Enables Teen to Walk Independently, Targeting Epilepsy's Genetic Root

A groundbreaking gene therapy has enabled a teenager with SCN2A-related developmental epileptic encephalopathy (DEE) to walk independently. The therapy, developed by an international team led by the University of California San Diego, targets proteins produced by disease-causing mutations. Over two years, the treatment significantly reduced seizures and improved developmental outcomes for two children. The therapy involves allele-selective antisense oligonucleotides (ASOs) that silence the mutated gene copy while preserving the normal one. This personalized approach has shown substantial benefits, including reduced seizure frequency and improved motor and language skills.

Blood Neurofilament Light Biomarker Promises to Transform Neurodegenerative Trials

Blood Neurofilament Light Biomarker Promises to Transform Neurodegenerative Trials

Blood neurofilament light (NfL) is gaining attention as a promising biomarker for measuring treatment response in neurodegenerative disease trials. A recent review highlights its potential to streamline drug development by providing earlier and more objective measures of treatment efficacy. The review analyzed 49 studies across various conditions, including multiple sclerosis and Alzheimer's disease, finding that reductions in blood NfL often correlated with improvements in primary efficacy outcomes. This suggests that blood sampling could offer a less invasive alternative to cerebrospinal fluid analysis in clinical trials.

Mini Brains Offer New Hope for Multiple Sclerosis Treatment

Mini Brains Offer New Hope for Multiple Sclerosis Treatment

Researchers at The Florey Institute of Neuroscience and Mental Health are using laboratory-grown 'mini brains' to study and potentially repair damage caused by multiple sclerosis (MS). Led by Dr. Samantha Barton, the team is focusing on myelin, the protective coating around nerve fibers, using 3D brain models created from human stem cells. This innovative approach aims to address the limitations of current MS treatments, which manage symptoms but do not repair existing damage.

Study Links Financial Hardship to Brain Shrinkage and Cognitive Decline

Study Links Financial Hardship to Brain Shrinkage and Cognitive Decline

A study published in the journal Innovation in Aging has found that persistent financial hardship is associated with cognitive decline and brain tissue shrinkage. The research tracked nearly 3,000 British adults over 70 years, examining the impact of low income and difficulty meeting basic needs on memory and processing speed. Participants facing financial stress showed lower cognitive scores by age 53 and signs of brain shrinkage in later life. The study highlights the role of chronic stress and socioeconomic disadvantage in affecting brain health.